Sendero Wealth Management LLC Acquires 1,738 Shares of Pfizer Inc. (NYSE:PFE)

Sendero Wealth Management LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 19.0% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 10,899 shares of the biopharmaceutical company’s stock after acquiring an additional 1,738 shares during the quarter. Sendero Wealth Management LLC’s holdings in Pfizer were worth $302,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. GoalVest Advisory LLC grew its stake in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth approximately $32,000. VisionPoint Advisory Group LLC lifted its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new position in shares of Pfizer in the fourth quarter worth approximately $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of a number of recent analyst reports. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $35.86.

Pfizer Stock Up 0.7 %

Shares of NYSE:PFE traded up $0.19 during midday trading on Friday, reaching $27.99. The company’s stock had a trading volume of 33,161,255 shares, compared to its average volume of 40,908,660. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The firm has a 50 day moving average of $27.90 and a 200-day moving average of $27.69. The firm has a market capitalization of $158.61 billion, a P/E ratio of -466.42, a PEG ratio of 1.08 and a beta of 0.70. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the prior year, the company earned $1.23 earnings per share. The business’s revenue was down 19.5% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.